Gilead Sciences exercised its possibility license a Kymera Therapeutics’ protein-degrading drug designed to get rid of the cancer-driving protein CDK2. In the meantime, Roche’s new partnership with C4 Therapeutics is targeted on growing degrader antibody drug conjugates for undisclosed most cancers targets.
The submit Gilead and Roche Guess on Protein Degraders for Their Most cancers Drug Pipelines appeared first on MedCity Information.
